Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41561
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Saha, Abinit | - |
dc.creator | Sharma, Ashish Ranjan | - |
dc.creator | Bhattacharya, Manojit | - |
dc.creator | Sharma, Garima | - |
dc.creator | Lee, Sang-Soo | - |
dc.creator | Chakraborty, Chiranjib | - |
dc.date.accessioned | 2020-06-24T16:27:02Z | - |
dc.date.available | 2020-06-24T16:27:02Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | SAHA, A. et al. Tocilizumab: a therapeutic option for the treatment of Cytokine Storm Syndrome in COVID-19. Archives of Medical Research, [S.l.], 2020. No prelo. | pt_BR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0188440920307827 | pt_BR |
dc.identifier.uri | http://repositorio.ufla.br/jspui/handle/1/41561 | - |
dc.description.abstract | Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-κB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-κB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab. | pt_BR |
dc.language | en_US | pt_BR |
dc.publisher | Elsevier | pt_BR |
dc.rights | restrictAccess | pt_BR |
dc.source | Archives of Medical Research | pt_BR |
dc.subject | Tocilizumab | pt_BR |
dc.subject | Cytokine storm syndrome | pt_BR |
dc.subject | COVID-19 | pt_BR |
dc.title | Tocilizumab: a therapeutic option for the treatment of Cytokine Storm Syndrome in COVID-19 | pt_BR |
dc.type | Artigo | pt_BR |
Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.